Skip to Main Content

drug pricing

Drug pricing news from STAT. Stories include Doctors Without Borders seeking a lower cost for HIV drugs, Genentech slow-walking ovarian cancer therapy, legal cases related to pharmacy benefit managers (PBMs), and the use of continuation patents to curb competition and protect profits.

Latest

The Readout Damian Garde

STAT Plus: With Ozempic, Wall Street moves on from a whole other class of medicines

The Readout Meghana Keshavan

STAT Plus: NIH funds expanded access projects for ALS

The Readout Damian Garde

Moderna’s plan to make a single vaccine for Covid, influenza, and RSV is on track

Special Report Andrew Joseph

STAT Plus: Gene therapy makers wonder if they can make a profit in Europe. Patients fear being left behind — again

Politics Rachel Cohrs

STAT Plus: Court allows Medicare drug price negotiation to proceed

Pharmalot Ed Silverman

STAT Plus: Unitaid slams J&J over pricing and patents for a tuberculosis drug

Pharma Annalisa Merelli

STAT Plus: Just how much money do drugmakers gain from patent extensions?

Pharma Jason Mast

STAT Plus: AstraZeneca CEO Pascal Soriot proposes a novel fix to the drug pricing law’s alleged cancer problem

All Coverage

Pharmalot Damian Garde

STAT Plus: Pharmalittle: Regeneron wins a delayed approval; Bristol, J&J likely to face pricing negotiation

Pharmalot Ed Silverman

STAT Plus: ViiV Healthcare and Doctors Without Borders tussle over contract terms for an HIV drug

advertisement

Insurance Bob Herman

STAT Plus: Blue Shield of California overhauls drug pricing operation — by adding more vendors

Pharmalot Ed Silverman

STAT Plus: U.S. appeals court strikes down key provisions in Oklahoma law that regulates PBMs

Matt's Take Matthew Herper

STAT Plus: From drug shortages to high prices, U.S. system’s shortcomings have deep roots

Pharmalot Ed Silverman

STAT Plus: More drugmakers are filing continuation patents that sideline generic competition

Pharmalot Ed Silverman

STAT Plus: Nektar Therapeutics sues Lilly for ‘misconduct’ in drug development deal

Pharmalot Ed Silverman

STAT Plus: Vertex faces renewed calls to widen access to its cystic fibrosis medicines in poor countries

Politics John Wilkerson

STAT Plus: Senate panel advances PBM reform — but sidesteps anything controversial

Politics Rachel Cohrs and John Wilkerson

STAT Plus: Democrats already want to expand Medicare drug price negotiation

Politics Rachel Cohrs

STAT Plus: Congress’s PBM reforms won’t end America’s drug pricing woes. Here’s what they would do

Pharmalot Ed Silverman

STAT Plus: South Africa faces court hearing over opaque Covid-19 vaccine contracts

Pharmalot Ed Silverman

STAT Plus: Pharmalittle: Biogen to slash 1,000 more jobs; key House panel proposes lowering Medicare out-of-pocket drug costs

Politics Rachel Cohrs

STAT Plus: Key House panel proposes lowering out-of-pocket drug costs in Medicare

First Opinion Keith Ericson and Tal Gross

Drug pricing and the ‘impossible trinity’ for patients

Politics John Wilkerson

STAT Plus: Bernie Sanders wants to replace drug patents with prizes for breakthrough medicines

Video Chat Ed Silverman

STAT Plus: STAT Virtual Event: The State of Biosimilars: What to Watch

Pharmalot Ed Silverman

STAT Plus: Colombian government explores compulsory licensing for an HIV drug

Politics Rachel Cohrs

STAT Plus: How a key Senate committee is planning to regulate pharmacy benefit managers

Politics Sarah Owermohle

STAT Plus: Biden’s NIH nominee is languishing in Congress — alarming public health advocates

Hospitals Rachel Cohrs

STAT Plus: Medicare wants to send $9 billion to 340B hospitals — coupled with cuts